✦ LIBER ✦

Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer

✍ Scribed by Gabriele K. Beckmann; Florian Hoppe; Leo Pfreundner; Michael P. Flentje

Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 267 KB
Volume: 27
Category: Article
ISSN: 1043-3074
DOI: 10.1002/hed.20111

No coin nor oath required. For personal study only.

✦ Synopsis

Background:

The purpose of this study was to determine the feasibility and efficacy of hyperfractionated accelerated radiotherapy (hfrcb) combined with simultaneous chemotherapy with weekly cisplatin (cddp) in locally advanced inoperable head and neck cancer.

Methods:

From august 1999 to december 2002, 37 patients (median age, 59 years) with union internationale contre le cancer stage iii (n = 2) and stage iv (n = 35) squamous cell cancer of the oropharynx and hypopharynx were treated in a prospective phase i/ii trial. concomitant boost radiotherapy (1.8 gy, days 1-38 and 1.5 gy boost, days 22-38, twice daily with at least a 6-hour interval; total dose 69.9 gy) and simultaneous cisplatin, 40 mg/m2 weekly, were given.

Results:

The median treatment duration was 42 days (range, 38-46 days). toxicity was manageable, with neutropenia grade iii/iv and thrombocytopenia grade iv in seven and one patients, and mucositis grade iii/ iv in 27 and five patients, respectively. chemotherapy was restricted to four weekly applications in 29 patients mainly because of mucosal toxicity with a median dose intensity of 160 mg/m2 (0-200) of cisplatin in 5.5 weeks. with a median follow-up of 28 months for living patients, the 2-year overall survival rate was 67%. the median overall and relapse-free survival times were 36 and 31 months, respectively.

Conclusion:

Hfrcb in combination with weekly cisplatin achieves a high rate of locoregional control and survival. four weekly cycles of 40 mg/m2 cisplatin seem to be the dose limit for most patients.

📜 SIMILAR VOLUMES

Concomitant weekly cisplatin and altered

Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer

✍ Heather E. Newlin; Robert J. Amdur; Charles E. Riggs; Christopher G. Morris; Jes 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 144 KB 👁 1 views

## Abstract ## BACKGROUND: Both concomitant chemotherapy and altered fractionation radiotherapy (RT) have been shown to improve outcomes for patients with locoregionally advanced head and neck squamous cell carcinomas. However, both strategies also increase acute toxicity, and it is questionable w

Improved results with accelerated hyperf

Improved results with accelerated hyperfractionated radiotherapy of advanced head and neck cancer

✍ Felix Leborgne; Eduardo Zubizarreta; Jack Fowler; Bettys Ortega; Julieta Mezzera 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 309 KB 👁 2 views

A retrospective study on local tumor control, survival, and complications of conventional irradiation vs. accelerated hyperfractionated irradiation in patients with selected head and neck cancer sites was undertaken. A total of 1,007 consecutive patients treated with radiation alone for cure from 19

Early experience with a hybrid accelerat

Early experience with a hybrid accelerated radiotherapy schedule for locally advanced head and neck cancer

✍ Sandra Nuyts; Piet Dirix; Robert Hermans; Vincent Vander Poorten; Pierre Delaere 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 326 KB 👁 1 views

## Abstract ## Background. Our aim was to determine feasibility and efficacy of a hybrid radiotherapy schedule in locally advanced head and neck cancer. ## Methods. Seventy‐three patients with locally advanced head and neck cancer were irradiated according to a hybrid accelerated schedule consis

Weekly 5-fluorouracil plus cisplatin for

Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer

✍ Young Joo Lee; Chang Geol Lee; Byoung Chul Cho; Gwi Eon Kim; Hye Jin Choi; Eun C 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 160 KB

## Abstract ## Background. In locally advanced head and neck cancer, concurrent chemoradiotherapy (CRT) with combined 5‐fluorouracil (5‐FU) and cisplatin has increased acute toxicities as well as survival. Once‐weekly chemotherapeutic administration schedule may reduce severe toxicities. Thus, we

Advanced head and neck carcinoma in wome

Advanced head and neck carcinoma in women : Treatment outcomes may not improve with accelerated hyperfractionated radiotherapy

✍ Felix Leborgne; José H. Leborgne; Jack F. Fowler; Eduardo Zubizarreta; Julieta M 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 169 KB 👁 2 views

## Background: The authors undertook a retrospective study on local tumor control, survival, and complications of conventional irradiation compared with accelerated hyperfractionated irradiation in women with selected head and neck tumor sites. ## Methods: One hundred eight consecutive women who

Multidrug chemotherapy using bleomycin,

Multidrug chemotherapy using bleomycin, methotrexate, and cisplatin combined with radical radiotherapy in advanced head and neck cancer

✍ Dr. J. Zidan; A. Kuten; Y. Cohen; E. Robinson 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 266 KB 👁 2 views

Thirty-one patients with Stage III-IV head and neck squamous cell cancer were treated by three courses of combination chemotherapy using bleomycin, methotrexate, and cisplatin followed by a radical course of radiation and in two cases by surgery. Of 29 evaluable patients, 4 (14%) achieved complete r